Comparative study of frequency of different lymphocytes subpopulation in peripheral blood of patients with prostate cancer and benign prostatic hyperplasia

Wiener Klinische Wochenschrift

Volumn 123, Issue 23-24, 2011, Pages 718-725

  Sotosek, Stanislav ^a   Tokmadzic, Vlatka Sotosek ^b   Mrakovcic Sutic, Ines ^b   Tomas, Maja Ilic ^b   Dominovic, Marin ^b   Tulic, Vera ^b   Sutic, Ivana ^b   Maricic, Antun ^a   Sokolic, Jadranko ^b   Sustic, Alan ^b  

^a KBC RIJEKA   (Croatia)

^b UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

Benign prostatic hyperplasia; IFN ; IL 4; NK cells; NKT cells; Prostatic cancer; T lymphocytes; T regulatory cells

Indexed keywords

CD56 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 4; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; BLOOD; CANCER GROWTH; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FLOW CYTOMETRY; HUMAN; LEUKOCYTE; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSTATE CANCER; PROSTATE HYPERTROPHY; T LYMPHOCYTE;

ADULT; AGED; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 84856953887     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-011-0096-7     Document Type: Article

References (25)

1. Webber R. Benign prostatic hyperplasia. Clin Evid 2006;15:1213-26.
2. Vutuc C, Schernhammer ES, Haidinger G, Waldhör T. Prostate cancer and prostate-specif c antigen (PSA) screening in Austria. Wien Klin Wochenschr 2005;117(13-14):457-61. (Pubitemid 41152495)
3. Zenzmaier C, Untergasser G, Berger P. Aging of the prostate epithelial stem/progenitor cell. Exp Gerontol 2008;43(11):981-5.
4. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 2009;36(4):403-15.
5. Klein EA, Silverman R. Inflammation, infection, and prostate cancer. Curr Opin Urol 2008;18(3):315-9. (Pubitemid 351489383)
6. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7(4):256-69. (Pubitemid 46486616)
7. Steiner GE, Djavan B, Kramer G, et al. The picture of the prostatic lymphokine network is becoming increasingly complex. Rev Urol 2002;4(4):171-7.
8. Robert G, Descazeaud A, Nicolaïew N, et al. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate 2009;69(16):1774-80.
9. Hussein MR, Al-Assiri M, Musalam AO. Phenotypic characterization of the inf ltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. Exp Mol Pathol 2009;86(2):108-13.
10. Caligiuri MA. Human natural killer cells Blood 2008;112(3):461-9.
11. Timmons BW, Cieslak T. Human natural killer cell subsets and acute exercise: a brief review. Exerc Immunol Rev 2008;14:8-23.
12. Dustin ML. The cellular context of T cell signaling. Immunity 2009;30(4):482-92.
13. Corthay A. How do regulatory T cells work? Scand J Immunol 2009;70(4):326-36.
14. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000;21:573-83.
15. Bianchi-Frias D, Vakar-Lopez F, Coleman IM, Plymate SR, Reed MJ, Nelson PS. The effects of aging on the molecular and cellular composition of the prostate microenvironment. PLoS One 2010;5(9). pii: e12501.
16. Schröder FH. Prostate cancer around the world. An overview. Urol Oncol 2010;28(6):663-7.
17. Parsons JK, Kashef IC. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol 2008;53(6):1228-35.
18. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol 2005;40(3):121-8. (Pubitemid 40343002)
19. Ricke WA, Wang Y, Kurita T, Hayward SW, Cunha GR. Hormonal and stromal regulation of normal and neoplastic prostatic growth. Prog Mol Subcell Biol 2005;40:183-216.
20. Nandeesha H. Benign prostatic hyperplasia: dietary and metabolic risk factors. Int Urol Nephrol 2008;40(3):649-56.
21. Miller AM, Lundberg K, Ozenci V, et al. CD4+CD25 (high) T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177(10):7398-405. (Pubitemid 44715110)
22. Yokokawa J, Cereda V, Remondo C, et al. Enhanced functionality of CD4+CD25 (high) FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008;14(4):1032-40. (Pubitemid 351302548)
23. Van Kaer L. NKT cells: T lymphocytes with innate effector functions. Curr Opin Immunol 2007;19(3):354-64. (Pubitemid 46687006)
24. Oikawa T, Kawai K, Ishiwata I, Ohno T, Akaza H. Induction of potent antitumour natural-killer cells from peripheral blood of patients with advanced prostate cancer. BJU Int 2003;92(9):1009-15. (Pubitemid 37548286)
25. Filella X, Alcover J, Zarco MA, Beardo P, Molina R, Ballesta AM. Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate. 2000;44(4):271-4.